Medtronic’s Resolute Onyx stent shows benefits in new study

Medtronic has announced the findings of a new clinical trial that demonstrate the benefits its Resolute Onyx drug-eluting stent can offer to patients with specific needs.

In the new study, the two-millimetre stent met its primary endpoint of target lesion failure improvements after one year when used to treat coronary artery disease in extra-small vessels.

Around 65 percent of extra-small vessels are located in critical locations of the heart, making them challenging to treat. Resolute Onyx has been specifically designed to yield excellent clinical outcomes in patients affected by this issue.

Jason Weidman, vice-president and general manager of Medtronic's coronary and renal denervation business, said: "These initial results reinforce the unique design of the Resolute Onyx, providing physicians and patients around the globe with the gold standard in drug-eluting stents."

Resolute Onyx incorporates Core Wire Technology, a method of stent manufacturing that involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct. This enables greater deliverability and conformability to the vessel wall.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.